|
Epigenomics AG / Key word(s): Agreement 09.01.2014 / 08:30 Berlin, Germany, Germantown, MD, U.S.A. and Wuhan and Beijing, China, January 9, 2014 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTC: EPGNY), a German-American cancer molecular diagnostics company, and Wuhan Kindstar Clinical Diagnostics Co. Ltd (Kindstar), a leading Chinese clinical diagnostics company, announced today that both parties entered into a licensing and supply agreement for Epigenomics’ Epi proLung(R) tissue assay for the Chinese market.
Under the terms of the agreement Kindstar will commercialize the Epi proLung(R) assay for use in lung cancer diagnosis in China. Epigenomics will retain the responsibility to manufacture and supply the product and to provide support with respect to medical and regulatory considerations. Noel Doheny, CEO of Epigenomics’ US subsidiary, commented: ‘We are excited to enter into this agreement regarding our Epi proLung(R) tissue assay with Kindstar. The ability to leverage the established know-how and existing and well-functioning reference laboratory infrastructure of our new partner will provide a significant advantage for Epigenomics in the market introduction and technology roll-out of Epi proLung(R) in China. This agreement allows for a dual commercialization effort to apply Epigenomics’ patented methods and its biomarker for lung cancer diagnosis in the Chinese market.’ ‘Epigenomics’ Epi proLung(R) assay fills an unmet need in current lung cancer diagnosis,’ added Shiang Huang, M.D., CEO of Kindstar. ‘We are very pleased to add Epi proLung(R) to the suite of cancer testing services we offer to Chinese physicians. We look forward to collaborating with Epigenomics on this assay and to the opportunity to expand our partnership on additional tests for the Chinese market.’ About Epigenomics Epigenomics (www.epigenomics.com) is a molecular diagnostics company developing and commercializing a pipeline of proprietary products for cancer. The Company’s products enable doctors to diagnose cancer earlier and more accurately, leading to improved outcomes for patients. Epigenomics’ lead product, Epi proColon(R), is a blood-based test for the early detection of colorectal cancer, which is currently marketed in Europe and is under regulatory review by the FDA for the U.S.A. Additionally, the company markets its tissue assay for use in lung cancer diagnosis, Epi proLung(R), in Europe. The Company’s technology and products have been validated through multiple partnerships with leading global diagnostic companies and testing laboratories. Epigenomics is an international company with operations in Europe and the U.S.A. About Kindstar Kindstar (www.kindstarglobal.com), with laboratory facilities in Beijing, Shanghai and Wuhan, provides esoteric diagnostic testing services to hospitals and physicians in every province of China. Kindstar is the first and largest esoteric diagnostic testing business in China, providing laboratory testing services to over 3,300 Chinese hospitals, including 930 tertiary hospitals (classification for largest leading hospitals). Kindstar is becoming the partner of choice to physicians in China for advanced diagnostics in many medical specialties including hematology, oncology, infectious diseases and medical genetics. Contact Epigenomics AG Antje Zeise, Manager IR | PR For US press inquiries: Epigenomics, Inc. Contact Kindstar Clover Zhang Epigenomics legal disclaimer This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. The information contained in this communication does not constitute nor imply an offer to sell or transfer any product, and no product based on this technology is currently available for sale by Epigenomics in the United States or Canada. The analytical and clinical performance characteristics of any Epigenomics product based on this technology which may be sold at some future time in the U.S. have not been established. End of Corporate News 09.01.2014 Dissemination of a Corporate News, transmitted by DGAP – a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. DGAP’s Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English | |
| Company: | Epigenomics AG | |
| Kleine Präsidentenstraße 1 | ||
| 10178 Berlin | ||
| Germany | ||
| Phone: | +49 30 24345-0 | |
| Fax: | +49 30 24345-555 | |
| E-mail: | ir@epigenomics.com | |
| Internet: | www.epigenomics.com | |
| ISIN: | DE000A1K0516 | |
| WKN: | A1K051 | |
| Listed: | Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, München, Stuttgart | |
| End of News | DGAP News-Service |
|
|
| 247355 09.01.2014 |